Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.60 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.60 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.60 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.60 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.60 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.60 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.60 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.60 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.60 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.60 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.60 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.60 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.60 |
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.49 |
| ▸ | SCN8A known ✓ | Q9UQD0 | 2/20 | 0.47 |
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.47 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 known ✓ | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC10 known ✓ | Q969S8 | 1/20 | 0.47 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29562116 | 1.00 | POLB (0.62) | POLBCYP1A2CYP2D6KDM4EADRA1A | |
| SCHEMBL1603187 | 0.99 | CYP1A2 (0.61) | POLBCYP1A2CYP2D6KDM4EADRA1A | |
| Hydrochloric Acid SCHEMBL1603322 | 0.93 | POLB (0.69) | POLBCYP1A2CYP2D6KDM4EADRA1A | |
| Hydrochloric Acid SCHEMBL29563395 | 0.93 | POLB (0.69) | POLBCYP1A2CYP2D6KDM4EADRA1A | |
| SCHEMBL22849936 | 0.84 | SLC16A3 (0.64) | POLBCYP1A2CYP2D6KDM4EADRA1A | |
| SCHEMBL17510202 | 0.82 | SLC16A3 (0.59) | POLBCYP1A2CYP2D6KDM4EADRA1A | |
| SCHEMBL929060 | 0.82 | SLC16A3 (0.59) | POLBCYP1A2CYP2D6KDM4EADRA1A | |
| SCHEMBL22849913 | 0.82 | SLC16A3 (0.62) | POLBCYP1A2CYP2D6KDM4EADRA1A | |
| SCHEMBL29562290 | 0.80 | SLC16A3 (0.57) | POLBCYP1A2CYP2D6KDM4EADRA1A | |
| SCHEMBL927053 | 0.80 | SLC16A3 (0.57) | POLBCYP1A2CYP2D6KDM4EADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3990433-B1 | PROCESSES OF MAKING 2-((1-BENZYL-1H-INDAZOL-3-YL)METHOXY)-2-METHYLPROPANOIC ACID AND ITS DERIVATIVES | TRANSLATUM MEDICUS INC (CA) | 2026-05-20 | — | — | EP | disclosed |
| US-12122751-B2 | Processes of making 2-((1-benzyl-1H-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives | Translatum Medicus Inc. (CA) | 2024-10-22 | — | — | US | disclosed |
| US-20240025859-A1 | PROCESSES OF MAKING 2-((1-BENZYL-1H-INDAZOL-3-YL)METHOXY)-2-METHYLPROPANOIC ACID AND ITS DERIVATIVES | Translatum Medicus Inc. (CA) | 2024-01-25 | — | — | US | disclosed |
| US-11753382-B2 | Processes of making 2-((1-benzyl-1H-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives | Translatum Medicus Inc. (CA) | 2023-09-12 | — | — | US | disclosed |
| US-20220363646-A1 | PROCESSES OF MAKING 2-((1-BENZYL-1H-INDAZOL-3-YL)METHOXY)-2-METHYLPROPANOIC ACID AND ITS DERIVATIVES | Translatum Medicus Inc. (CA) | 2022-11-17 | — | — | US | disclosed |
| US-20190336482-A1 | COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING OCULAR DISORDERS | TRANSLATUM MEDICUS INC (CA) | 2019-11-07 | — | — | US | disclosed |
| EP-2262778-B1 | 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CXCR1 AND P40 | ACRAF (IT) | 2019-08-21 | — | — | EP | disclosed |
| US-20180221339-A1 | COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING OCULAR DISORDERS | TRANSLATUM MEDICUS, INC. (CA) | 2018-08-09 | — | — | US | disclosed |
| EP-3310353-A1 | COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING OCULAR DISORDERS | Translatum Medicus, Inc. (CA) | 2018-04-25 | — | — | EP | disclosed |
| WO-2016203313-A1 | COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING OCULAR DISORDERS | TRANSLATUM MEDICUS, INC. (CA) | 2016-12-22 | — | — | WO | disclosed |
| US-9255073-B2 | 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40 | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2016-02-09 | — | — | US | disclosed |
| US-20130267704-A1 | 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 AND P40 | AZIENDE CHIM. RIUN. ANG. FRANC. A.C.R.A.F. S.P.A. (IT) | 2013-10-10 | — | — | US | disclosed |
| US-8461194-B2 | 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and P40 | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A. C. R. A. F. S. P. A. (IT) | 2013-06-11 | — | — | US | disclosed |
| US-20110082141-A1 | 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 AND P40 | AZIENDE CHIM. RIUN.ANG.FRANC. A.C.R.A.F. S.p.A. (IT) | 2011-04-07 | — | — | US | disclosed |
| EP-2262778-A2 | 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CXCR1 AND P40 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. (IT) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009109616-A2 | NOVEL 1-BENZIL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 AND P40 | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12122751-B2 | Processes of making 2-((1-benzyl-1H-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives | PCMT1, ICMT, FNTA | ADRA1A 2834/4885CHRM2 3226/4885HTR1A 1592/4885 |
| US-20180221339-A1 | COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING OCULAR DISORDERS | UACA, PDE6C, EYA3 | ADRA1A 2422/4885CHRM2 2967/4885HTR1A 3408/4885 |
| US-20130267704-A1 | 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 AND P40 | CX3CR1, CCR2, CCR5 | ADRA1A 426/4885CHRM2 202/4885HTR1A 479/4885 |
| US-11753382-B2 | Processes of making 2-((1-benzyl-1H-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives | PCMT1, ICMT, FNTA | ADRA1A 2834/4885CHRM2 3226/4885HTR1A 1592/4885 |
| US-20240025859-A1 | PROCESSES OF MAKING 2-((1-BENZYL-1H-INDAZOL-3-YL)METHOXY)-2-METHYLPROPANOIC ACID AND ITS DERIVATIVES | PCMT1, ICMT, FNTA | ADRA1A 2834/4885CHRM2 3226/4885HTR1A 1592/4885 |
| US-20190336482-A1 | COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING OCULAR DISORDERS | UACA, PDE6C, EYA3 | ADRA1A 2422/4885CHRM2 2967/4885HTR1A 3408/4885 |
| US-20110082141-A1 | 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 AND P40 | CX3CR1, CCR2, CCR5 | ADRA1A 426/4885CHRM2 202/4885HTR1A 479/4885 |
| US-20220363646-A1 | PROCESSES OF MAKING 2-((1-BENZYL-1H-INDAZOL-3-YL)METHOXY)-2-METHYLPROPANOIC ACID AND ITS DERIVATIVES | PCMT1, ICMT, FNTA | ADRA1A 2834/4885CHRM2 3226/4885HTR1A 1592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.